
Jay-Jiguang Zhu
Associated articles
OJEMB, Featured Articles
Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation
Naze G. Avci, Nitin Tandon, Yasemin M. Akay, Yoshua Esquenazi, Hui Xia, Jay-Jiguang Zhu, Metin Akay, Lisa H. Schmitt
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, accounting for 50% of all cases. GBM patients have a five-year survival rate of merely 5.6% and a median overall survival of 14.6 months with the “Stupp” regimen, 20.9...
Read more
Posted on 27 FEB 2020